Crescent Biopharma to Present at May Investor Conferences
Rhea-AI Summary
Crescent Biopharma (Nasdaq: CBIO) announced management presentations at three investor conferences in May 2026: BofA Securities Healthcare Conference (fireside chat, May 13), Stifel Virtual Targeted Oncology Forum (virtual fireside chat, May 20), and Cowen Oncology Innovation Summit (virtual fireside chat, May 26).
A live webcast will be available in the Investors section of Crescent's website and replays will be accessible for 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – CBIO
In the May 6 session, CBIO declined 0.11%, reflecting a mild negative market reaction. Argus tracked a peak move of +13.2% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 29 | Q1 2026 earnings | Positive | +6.8% | Reported Q1 2026 results, cash of $189.2M, and pipeline timelines into 2027. |
| Apr 24 | Inducement awards | Neutral | +1.4% | Granted options over 12,525 shares with 10‑year term and $25.70 exercise price. |
| Mar 27 | Inducement awards | Neutral | +9.6% | Awarded options for 35,325 shares at $13.50, vesting over four years. |
| Mar 6 | Inducement awards | Neutral | -0.4% | Announced 45,675 option shares at $11.33 with standard 10‑year term and vesting. |
| Feb 26 | FY 2025 earnings | Positive | -1.2% | Reported 2025 results, Kelun partnership, CR‑001 IND clearance, and $185M private placement. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news (earnings and inducement grants) often coincided with positive or modestly positive next‑day moves, with occasional divergences on larger fundamental updates.
Over the past few months, Crescent Biopharma has focused on funding and pipeline visibility. Q4 and full‑year 2025 results on Feb 26, 2026 highlighted a substantial private placement supporting operations into 2028. Subsequent inducement award announcements in March and April granted options over tens of thousands of shares with 10‑year terms. On Apr 29, 2026, Q1 2026 results reiterated cash of $189.2 million and ongoing CR‑001 development. Today’s investor‑conference update fits a pattern of sustained investor outreach around these milestones.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in May:
- BofA Securities 2026 Healthcare Conference, fireside chat on Wednesday, May 13, 2026 at 4:20 p.m. PT (7:20 p.m. ET) in Las Vegas
- 2026 Stifel Virtual Targeted Oncology Forum, virtual fireside chat on Wednesday, May 20, 2026 at 2:30 p.m. ET
- TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA, virtual fireside chat on Tuesday, May 26, 2026 at 11:30 a.m. ET
A live webcast of each presentation will be available in the Investors section of Crescent's website at https://investors.crescentbiopharma.com/events-presentations, and a replay will be accessible for 90 days.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
Contacts
Investors
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586
Media
Jenna Poist
Director, Corporate Communications
jenna.poist@crescentbiopharma.com
781-671-5019
